Biopharmaceuticals Stocks List

Recent Signals

Date Stock Signal Type
2019-12-11 BMRN Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2019-12-11 BMRN 1,2,3 Pullback Bullish Bullish Swing Setup
2019-12-11 BMRN 20 DMA Support Bullish
2019-12-11 DYAI 20 DMA Resistance Bearish
2019-12-11 HAYN Bollinger Band Squeeze Range Contraction
2019-12-11 HAYN New 52 Week Closing High Bullish
2019-12-11 HAYN Upper Bollinger Band Walk Strength
2019-12-11 IBIO MACD Bullish Centerline Cross Bullish
2019-12-11 IBIO 1,2,3 Pullback Bullish Bullish Swing Setup
2019-12-11 IBIO 50 DMA Resistance Bearish
2019-12-11 IBIO Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2019-12-11 NVO Narrow Range Bar Range Contraction

A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial.
Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Specialty drugs, a recent classification of pharmaceuticals, are high-cost drugs that are often biologics. The European Medicines Agency uses the term advanced therapy medicinal products (ATMPs) for medicines for human use that are "based on genes, cells, or tissue engineering", including gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and combinations thereof. Within EMA contexts, the term advanced therapies refers specifically to ATMPs, although that term is rather nonspecific outside those contexts.
Gene-based and cellular biologics, for example, often are at the forefront of biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available.In some jurisdictions, biologics are regulated via different pathways than other small molecule drugs and medical devices.The term biopharmacology is sometimes used to describe the branch of pharmacology that studies biopharmaceuticals.

More about Biopharmaceuticals